[Form 4] Corcept Therapeutics Inc. Insider Trading Activity
William Guyer, Chief Development Officer of Corcept Therapeutics (CORT) reported insider transactions dated 08/08/2025. The Form 4 shows derivative and non-derivative activity executed pursuant to a 10b5-1 plan adopted on 11/27/2024. The filing reports acquisition in Table II of a stock option granting the right to buy 35,007 shares with an exercise price of $21.65; that option is shown as fully exercisable and carries an expiration date of 09/01/2031. Table II lists 350,000 derivative securities beneficially owned following the reported transaction.
Table I records non-derivative movements on the same date, including a reported disposition coded S of 35,007 common shares at a price of $71.77. The two Table I lines display reported beneficial ownership amounts of 40,494 and 5,487 shares respectively after the reported transactions. The Form notes the 10b5-1 plan governed the transactions.
William Guyer, Chief Development Officer di Corcept Therapeutics (CORT) ha segnalato operazioni di insider datate 08/08/2025. Il Form 4 evidenzia attività derivate e non derivate eseguite ai sensi di un piano 10b5-1 adottato il 11/27/2024. La comunicazione riporta in Tabella II l'acquisizione di un'opzione su azioni che conferisce il diritto di acquistare 35,007 azioni al prezzo di esercizio di $21.65; tale opzione risulta pienamente esercitabile e ha scadenza il 09/01/2031. La Tabella II indica il possesso di 350,000 titoli derivati a seguito della transazione segnalata.
La Tabella I registra movimenti non derivati nella stessa data, inclusa una cessione indicata con codice S di 35,007 azioni ordinarie a un prezzo di $71.77. Le due righe della Tabella I mostrano livelli di proprietà effettiva pari rispettivamente a 40,494 e 5,487 azioni dopo le operazioni riportate. Il Form specifica che le transazioni sono state regolate dal piano 10b5-1.
William Guyer, Chief Development Officer de Corcept Therapeutics (CORT) informó transacciones de insider con fecha 08/08/2025. El Form 4 muestra actividad derivada y no derivada ejecutada en virtud de un plan 10b5-1 adoptado el 11/27/2024. La presentación reporta en la Tabla II la adquisición de una opción sobre acciones que otorga el derecho a comprar 35,007 acciones con un precio de ejercicio de $21.65; esa opción aparece como totalmente ejercitable y vence el 09/01/2031. La Tabla II lista 350,000 valores derivados en posesión tras la transacción informada.
La Tabla I registra movimientos no derivados en la misma fecha, incluyendo una disposición codificada S de 35,007 acciones ordinarias a un precio de $71.77. Las dos líneas de la Tabla I muestran posiciones beneficiarias de 40,494 y 5,487 acciones respectivamente después de las transacciones informadas. El Form indica que las operaciones se realizaron bajo el plan 10b5-1.
Corcept Therapeutics (CORT) Chief Development Officer인 William Guyer가 08/08/2025자 내부자 거래를 보고했습니다. Form 4는 11/27/2024에 채택된 10b5-1 계획에 따라 실행된 파생 및 비파생거래를 보여줍니다. 제출서에는 표 II에 $21.65 행사가로 35,007주를 매수할 권리를 부여하는 스톡옵션의 취득이 보고되어 있으며, 해당 옵션은 완전히 행사 가능하고 만료일은 09/01/2031로 기재되어 있습니다. 표 II는 보고된 거래 이후 350,000개의 파생증권을 사실상 보유하고 있음을 나타냅니다.
표 I에는 같은 날짜의 비파생 거래가 기록되어 있으며, S 코드로 표기된 35,007주 보통주 처분이 포함되어 있고 처분 가격은 $71.77입니다. 표 I의 두 항목은 보고된 거래 후 사실상 소유 수를 각각 40,494주와 5,487주로 표시합니다. 제출서에는 해당 거래들이 10b5-1 계획에 따라 이루어졌다고 명시되어 있습니다.
William Guyer, Chief Development Officer de Corcept Therapeutics (CORT), a déclaré des opérations d'initié en date du 08/08/2025. Le formulaire 4 montre des opérations dérivées et non dérivées effectuées en vertu d'un plan 10b5-1 adopté le 11/27/2024. Le dépôt indique, dans le tableau II, l'acquisition d'une option donnant le droit d'acheter 35,007 actions au prix d'exercice de $21.65 ; cette option est présentée comme pleinement exerçable et arrive à échéance le 09/01/2031. Le tableau II recense 350,000 titres dérivés détenus après la transaction déclarée.
Le tableau I enregistre des mouvements non dérivés à la même date, y compris une cession codée S de 35,007 actions ordinaires au prix de $71.77. Les deux lignes du tableau I affichent des positions bénéficiaires de 40,494 et 5,487 actions respectivement après les opérations déclarées. Le formulaire précise que les transactions ont été encadrées par le plan 10b5-1.
William Guyer, Chief Development Officer von Corcept Therapeutics (CORT), meldete Insider-Transaktionen datiert 08/08/2025. Das Form 4 zeigt derivative und nicht-derivative Vorgänge, die gemäß einem 10b5-1-Plan, eingeführt am 11/27/2024, ausgeführt wurden. Die Einreichung berichtet in Tabelle II über den Erwerb einer Aktienoption, die das Recht gewährt, 35,007 Aktien zum Ausübungspreis von $21.65 zu kaufen; diese Option wird als voll ausübbar angegeben und läuft am 09/01/2031 ab. Tabelle II führt nach der gemeldeten Transaktion 350,000 derivativ gehaltene Wertpapiere auf.
Tabelle I verzeichnet am selben Datum nicht-derivative Bewegungen, darunter eine mit dem Code S gemeldete Veräußerung von 35,007 Stammaktien zu einem Preis von $71.77. Die beiden Zeilen in Tabelle I zeigen nach den Transaktionen jeweils eine wirtschaftliche Eigentümerschaft von 40,494 bzw. 5,487 Aktien. Das Formular weist darauf hin, dass die Transaktionen durch den 10b5-1-Plan geregelt wurden.
- Transactions executed under a 10b5-1 plan (adopted 11/27/2024), providing a preplanned, documented framework for the trades
- Acquisition reported of a stock option to buy 35,007 shares at an exercise price of $21.65, shown as fully exercisable
- Reported disposition of 35,007 common shares at $71.77 on 08/08/2025, which reduces direct common-stock holdings on the filing
- Table I shows reported common-stock beneficial ownership amounts of 40,494 and 5,487 on separate lines following the transactions, indicating changes in direct holdings
Insights
TL;DR: Transactions appear preplanned under a 10b5-1 plan, showing an option acquisition and a simultaneous share disposition; impact appears neutral.
The filing documents a 10b5-1-plan execution on 08/08/2025: a stock option to purchase 35,007 shares at $21.65 (fully exercisable, expiration 09/01/2031) and a reported sale of 35,007 common shares at $71.77. Table II reports 350,000 derivative securities beneficially owned following the transaction. From a trading-signal perspective, use of a prearranged plan reduces the information content of the trades for investors; the size and structure suggest routine insider compensation/exercise and plan-driven sales rather than ad-hoc liquidity-driven activity.
TL;DR: Use of a documented 10b5-1 plan and clear reporting supports transparency; transactions look procedural rather than opportunistic.
The Form 4 explicitly states the trades were executed under a 10b5-1 plan adopted on 11/27/2024, which provides an affirmative defense for preplanned trades. The reporting shows an increase in option-related holdings (right to buy 35,007 shares) and parallel sale activity of 35,007 common shares at $71.77. Reporting of post-transaction beneficial ownership (350,000 derivative securities and the two reported common-stock figures of 40,494 and 5,487) is complete and allows investors to track insider stake levels.
William Guyer, Chief Development Officer di Corcept Therapeutics (CORT) ha segnalato operazioni di insider datate 08/08/2025. Il Form 4 evidenzia attività derivate e non derivate eseguite ai sensi di un piano 10b5-1 adottato il 11/27/2024. La comunicazione riporta in Tabella II l'acquisizione di un'opzione su azioni che conferisce il diritto di acquistare 35,007 azioni al prezzo di esercizio di $21.65; tale opzione risulta pienamente esercitabile e ha scadenza il 09/01/2031. La Tabella II indica il possesso di 350,000 titoli derivati a seguito della transazione segnalata.
La Tabella I registra movimenti non derivati nella stessa data, inclusa una cessione indicata con codice S di 35,007 azioni ordinarie a un prezzo di $71.77. Le due righe della Tabella I mostrano livelli di proprietà effettiva pari rispettivamente a 40,494 e 5,487 azioni dopo le operazioni riportate. Il Form specifica che le transazioni sono state regolate dal piano 10b5-1.
William Guyer, Chief Development Officer de Corcept Therapeutics (CORT) informó transacciones de insider con fecha 08/08/2025. El Form 4 muestra actividad derivada y no derivada ejecutada en virtud de un plan 10b5-1 adoptado el 11/27/2024. La presentación reporta en la Tabla II la adquisición de una opción sobre acciones que otorga el derecho a comprar 35,007 acciones con un precio de ejercicio de $21.65; esa opción aparece como totalmente ejercitable y vence el 09/01/2031. La Tabla II lista 350,000 valores derivados en posesión tras la transacción informada.
La Tabla I registra movimientos no derivados en la misma fecha, incluyendo una disposición codificada S de 35,007 acciones ordinarias a un precio de $71.77. Las dos líneas de la Tabla I muestran posiciones beneficiarias de 40,494 y 5,487 acciones respectivamente después de las transacciones informadas. El Form indica que las operaciones se realizaron bajo el plan 10b5-1.
Corcept Therapeutics (CORT) Chief Development Officer인 William Guyer가 08/08/2025자 내부자 거래를 보고했습니다. Form 4는 11/27/2024에 채택된 10b5-1 계획에 따라 실행된 파생 및 비파생거래를 보여줍니다. 제출서에는 표 II에 $21.65 행사가로 35,007주를 매수할 권리를 부여하는 스톡옵션의 취득이 보고되어 있으며, 해당 옵션은 완전히 행사 가능하고 만료일은 09/01/2031로 기재되어 있습니다. 표 II는 보고된 거래 이후 350,000개의 파생증권을 사실상 보유하고 있음을 나타냅니다.
표 I에는 같은 날짜의 비파생 거래가 기록되어 있으며, S 코드로 표기된 35,007주 보통주 처분이 포함되어 있고 처분 가격은 $71.77입니다. 표 I의 두 항목은 보고된 거래 후 사실상 소유 수를 각각 40,494주와 5,487주로 표시합니다. 제출서에는 해당 거래들이 10b5-1 계획에 따라 이루어졌다고 명시되어 있습니다.
William Guyer, Chief Development Officer de Corcept Therapeutics (CORT), a déclaré des opérations d'initié en date du 08/08/2025. Le formulaire 4 montre des opérations dérivées et non dérivées effectuées en vertu d'un plan 10b5-1 adopté le 11/27/2024. Le dépôt indique, dans le tableau II, l'acquisition d'une option donnant le droit d'acheter 35,007 actions au prix d'exercice de $21.65 ; cette option est présentée comme pleinement exerçable et arrive à échéance le 09/01/2031. Le tableau II recense 350,000 titres dérivés détenus après la transaction déclarée.
Le tableau I enregistre des mouvements non dérivés à la même date, y compris une cession codée S de 35,007 actions ordinaires au prix de $71.77. Les deux lignes du tableau I affichent des positions bénéficiaires de 40,494 et 5,487 actions respectivement après les opérations déclarées. Le formulaire précise que les transactions ont été encadrées par le plan 10b5-1.
William Guyer, Chief Development Officer von Corcept Therapeutics (CORT), meldete Insider-Transaktionen datiert 08/08/2025. Das Form 4 zeigt derivative und nicht-derivative Vorgänge, die gemäß einem 10b5-1-Plan, eingeführt am 11/27/2024, ausgeführt wurden. Die Einreichung berichtet in Tabelle II über den Erwerb einer Aktienoption, die das Recht gewährt, 35,007 Aktien zum Ausübungspreis von $21.65 zu kaufen; diese Option wird als voll ausübbar angegeben und läuft am 09/01/2031 ab. Tabelle II führt nach der gemeldeten Transaktion 350,000 derivativ gehaltene Wertpapiere auf.
Tabelle I verzeichnet am selben Datum nicht-derivative Bewegungen, darunter eine mit dem Code S gemeldete Veräußerung von 35,007 Stammaktien zu einem Preis von $71.77. Die beiden Zeilen in Tabelle I zeigen nach den Transaktionen jeweils eine wirtschaftliche Eigentümerschaft von 40,494 bzw. 5,487 Aktien. Das Formular weist darauf hin, dass die Transaktionen durch den 10b5-1-Plan geregelt wurden.
FAQ
What insider transactions did William Guyer (CORT) report on the Form 4?
Were the trades by William Guyer part of a 10b5-1 plan?
How many derivative securities does Guyer beneficially own after the reported transactions?
What are the exercise price and expiration of the reported option?
How many common shares are reported as beneficially owned after the transactions?
